Actinium: Actinium. A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, atomic number 89, and atomic weight 227.0278. Its principal isotope is 227 and decays primarily by beta-emission.Thorium: Thorium. A radioactive element of the actinide series of metals. It has an atomic symbol Th, atomic number 90, and atomic weight 232.04. It is used as fuel in nuclear reactors to produce fissionable uranium isotopes. Because of its radioopacity, various thorium compounds are used to facilitate visualization in roentgenography.Trypsin Inhibitor, Kunitz Soybean: A high-molecular-weight protein (approximately 22,500) containing 198 amino acid residues. It is a strong inhibitor of trypsin and human plasmin.Serine Proteinase Inhibitors: Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.Protease Inhibitors: Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.Sea Anemones: The order Actiniaria, in the class ANTHOZOA, comprised of large, solitary polyps. All species are carnivorous.Cnidarian Venoms: Venoms from jellyfish; CORALS; SEA ANEMONES; etc. They contain hemo-, cardio-, dermo- , and neuro-toxic substances and probably ENZYMES. They include palytoxin, sarcophine, and anthopleurine.Trypsin Inhibitors: Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds.Sialic Acid Binding Ig-like Lectin 3: A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.Alpha Particles: Positively charged particles composed of two protons and two NEUTRONS, i.e. equivalent to HELIUM nuclei, which are emitted during disintegration of heavy ISOTOPES. Alpha rays have very strong ionizing power, but weak penetrability.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Executive Function: A set of cognitive functions that controls complex, goal-directed thought and behavior. Executive function involves multiple domains, such as CONCEPT FORMATION, goal management, cognitive flexibility, INHIBITION control, and WORKING MEMORY. Impaired executive function is seen in a range of disorders, e.g., SCHIZOPHRENIA; and ADHD.Ownership: The legal relation between an entity (individual, group, corporation, or-profit, secular, government) and an object. The object may be corporeal, such as equipment, or completely a creature of law, such as a patent; it may be movable, such as an animal, or immovable, such as a building.Pharmaceutical Preparations: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Posters as Topic: Single or multi-sheet notices made to attract attention to events, activities, causes, goods, or services. They are for display, usually in a public place and are chiefly pictorial.Congresses as Topic: Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.Erythrovirus: A genus of the family PARVOVIRIDAE, subfamily PARVOVIRINAE, and containing the type species PARVOVIRUS B19, HUMAN.Societies, Medical: Societies whose membership is limited to physicians.Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.Orphan Drug Production: Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others.Rare Diseases: A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.Pursuit, Smooth: Eye movements that are slow, continuous, and conjugate and occur when a fixed object is moved slowly.Biopharmaceutics: The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.Legislation, Drug: Laws concerned with manufacturing, dispensing, and marketing of drugs.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Appointments and Schedules: The different methods of scheduling patient visits, appointment systems, individual or group appointments, waiting times, waiting lists for hospitals, walk-in clinics, etc.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Lawyers: Persons whose profession is to give legal advice and assistance to clients and represent them in legal matters. (American Heritage Dictionary, 3d ed)Hematologic Diseases: Disorders of the blood and blood forming tissues.Schools, Medical: Educational institutions for individuals specializing in the field of medicine.Elements: Substances that comprise all matter. Each element is made up of atoms that are identical in number of electrons and protons and in nuclear charge, but may differ in mass or number of neutrons.Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].Acanthaceae: A plant family of the order Lamiales. It is characterized by simple leaves in opposite pairs, cystoliths (enlarged cells containing crystals of calcium carbonate), and bilaterally symmetrical and bisexual flowers that are usually crowded together. The common name for Ruellia of wild petunia is easily confused with PETUNIA.Isotopes: Atomic species differing in mass number but having the same atomic number. (Grant & Hackh's Chemical Dictionary, 5th ed)Isotope Labeling: Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms.Nitrogen Isotopes: Stable nitrogen atoms that have the same atomic number as the element nitrogen, but differ in atomic weight. N-15 is a stable nitrogen isotope.Oxygen Isotopes: Stable oxygen atoms that have the same atomic number as the element oxygen, but differ in atomic weight. O-17 and 18 are stable oxygen isotopes.African Americans: Persons living in the United States having origins in any of the black groups of Africa.Indians, North American: Individual members of North American ethnic groups with ancient historic ancestral origins in Asia.Science: The study of natural phenomena by observation, measurement, and experimentation.Asian Americans: Persons living in the United States having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent.Mexican Americans: Persons living in the United States of Mexican descent.United StatesHispanic Americans: Persons living in the United States of Mexican (MEXICAN AMERICANS), Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin. The concept does not include Brazilian Americans or Portuguese Americans.Passiflora: A plant genus of the family Passifloraceae, order Violales, subclass Dilleniidae, class Magnoliopsida. They are vines with ornamental flowers and edible fruit.Passifloraceae: A plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.Receptors, N-Acetylglucosamine: Cell surface receptors that bind to ACETYLGLUCOSAMINE.Wisteria: A plant genus of the family FABACEAE. Members contain wistarin, wisteria lectin and wistariasaponin.Plant Components, Aerial: The above-ground plant without the roots.

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. (1/23)

Preclinical evaluation of alpha particle-emitting 213Bi-labeled antibody constructs have demonstrated the specificity and potency of these agents in a variety of cancer systems. The transition of a 213Bi-radiolabeled antibody from a preclinical construct to a clinical drug represented a difficult task that involved development of reliable and validated methods to provide multiple MBq quantities of a pure, immunoreactive agent that met pharmaceutical standards to treat patients. METHODS: The methods used for the preparation of (213Bi)CHX-A-diethylenetriamine pentaacetic acid (DTPA)-HuM195, an alpha particle-emitting anti-CD33 antibody construct for therapy of myeloid leukemias, is used as a specific example. This article describes methods for reagent purification, drug labeling, radioprotection and chromatographic purification. Quality of the drug is evaluated using radiochemical incorporation and purity assays with instant thin-layer chromatography (ITLC) and high-performance liquid chromatography (HPLC), determination of cell-based antibody total immunereactivity, small animal safety, pyrogen level, sterility and radionuclidic purity. RESULTS: Sixty-seven doses were prepared. Individual doses ranged from 148 to 814 MBq. Specific activities ranged from 329 to 766 MBq/mg. The radiolabeling efficiency (median +/- SD) of CHX-A-DTPA-HuM195 with 213Bi was 81% +/- 9% (n = 67) after 9 min. The construct was purified by size-exclusion chromatography and was found to be 99% +/- 2% pure (n = 67) by either ITLC or HPLC methods. The immunoreactivity of (213Bi)CHX-A-DTPA-HuM195 was 89% +/- 9% (n = 44) and was independent of the specific activity. The formulated pharmaceutical was found to contain < or =4 +/- 1 EU/mL pyrogens (n = 66); all samples examined were sterile. An 225Ac radionuclidic impurity was present at a level of 0.04 +/- 0.03 x 10(-6)/mL (n = 10) in a product volume of 7.4 +/- 0.5 mL (n = 67). Each of the 67 doses was injected intravenously into patients without complication as part of a phase I clinical trial. CONCLUSION: These data show that 213Bi-labeled antibody constructs can be prepared and administered safely to humans at a wide range of therapeutic levels.  (+info)

Tumor therapy with targeted atomic nanogenerators. (2/23)

A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.  (+info)

Targeted actinium-225 in vivo generators for therapy of ovarian cancer. (3/23)

Advanced ovarian cancer is largely incurable, but initially it is frequently confined to the i.p. space. We explored i.p. radioimmunotherapy in a mouse model of human ovarian cancer. Use of a targeted actinium-225 ((225)Ac) in vivo generator of alpha particles exploits the extreme, selective cytotoxicity of alpha particles, while providing a feasible half-life to enable delivery to tumor. (225)Ac chelated with 2-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraacetic acid was conjugated to trastuzumab, an anti-HER-2/neu antibody. The radioimmunoconjugate was tested for immunoreactivity, internalization, and cytotoxicity using a human ovarian carcinoma cell line, SKOV3. (225)Ac-labeled trastuzumab retained immunoreactivity (50-90%), rapidly internalized into cells (50% at 2 h), and had an ED(50) of 1.3 nCi/ml after 4 days of incubation in vitro. i.p. administered (225)Ac- or (111)In-labeled trastuzumab behaved similarly with high tumor uptake [56-60% injected dose per gram (% ID/g) at 4 h, which increased to 65-70% ID/g at 24 h]. Tumor uptake was 3-5-fold higher than liver and spleen, the normal organs with the highest uptake. i.v. administration of (111)In-labeled trastuzumab produced slightly higher normal organ uptake compared with i.p.-administered (111)In-labeled trastuzumab. However, tumor uptake was low, 5%-26% ID/g. Therapy was examined with native trastuzumab and 220, 330, and 450 nCi of (225)Ac-labeled trastuzumab or (225)Ac-labeled control antibody at different dosing schedules. Therapy was initiated 9 days after tumor seeding. Groups of control mice and those administered native trastuzumab had median survivals of 33 and 37 or 44 days, respectively. Median survival was 52-126 days with (225)Ac-labeled trastuzumab at various doses and schedules, and 48-64 days for (225)Ac-labeled control the same schedules. Deaths from toxicity occurred with the highest activity levels. In conclusion, i.p. administration with a (225)Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity.  (+info)

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. (4/23)

Short-lived alpha-emitting isotopes individually conjugated to monoclonal antibodies have now reached human use, but little is still known about their toxicity. Use of antibody targetable (225)Ac nanogenerators is a new approach in the field of alpha-immunotherapy offering the advantage of a 10-d half-life (t(1/2)) and increased potency due to generation of 3 new atoms, yielding a total of 4 alpha-particles. However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG. METHODS: Cynomolgus monkeys were used to evaluate the toxicity of prototype (225)Ac nanogenerators. Monoclonal antibody HuM195 (anti-CD33) is the carrier for planned human clinical trials of (225)Ac; there are no CD33 sites in cynomolgus monkeys. In one experiment, 2 monkeys received a single intravenous dose of (225)Ac-HuM195 at 28 kBq/kg. This dose level is approximately the planned initial human dose. In another experiment, 2 animals received a dose escalation schedule of 3 increasing (225)Ac-HuM195 doses with a cumulative activity of 377 kBq/kg. The whole-blood t(1/2) of (225)Ac, ratios of (225)Ac to its ultimate alpha-emitting daughter nuclide (213)Bi, generation of monkey anti-HuM195 antibodies (MAHA), hematologic indices, serum biochemistries, and clinical parameters were measured. Monkeys were euthanized and examined histopathologically when the dose escalation reached toxicity. RESULTS: The blood t(1/2) of (225)Ac-HuM195 was 12 d, and 45% of generated (213)Bi daughters were cleared from the blood. MAHA production was not detected. Approximately 28 kBq/kg of (225)Ac caused no toxicity at 6 mo, whereas a cumulative dose of approximately 377 kBq/kg caused severe toxicity. In the cumulative dosing schedule, single doses of approximately 37 kBq/kg resulted in no toxicity at 6 wk. After approximately 130 kBq/kg were administered, no toxicity was observed for 13 wk. However, 28 wk after this second dose administration, mild anemia and increases of blood urea nitrogen and creatinine were detected. After administration of an additional 185 kBq/kg, toxicity became clinically apparent. Monkeys were euthanized 13 and 19 wk after the third dose administration (cumulative dose was 377 kBq/kg). Histopathologic evaluation revealed mainly renal tubular damage associated with interstitial fibrosis. CONCLUSION: (225)Ac nanogenerators may result in renal toxicity and anemia at high doses. The longer blood t(1/2) and the lack of target cell antigens in cynomolgus monkeys may increase toxicity compared with human application. Therefore, a dose level of at least 28 kBq/kg may be a safe starting dose in humans. Hematologic and renal function will require close surveillance during clinical trials.  (+info)

Engineered liposomes for potential alpha-particle therapy of metastatic cancer. (5/23)

Disseminated, metastatic cancer is frequently incurable. Targeted alpha-particle emitters hold great promise as therapeutic agents for disseminated disease. (225)Ac is a radionuclide generator that has a 10-d half-life and results in alpha-emitting daughter elements ((221)Fr, (217)At, (213)Bi) that lead to the emission of a total of 4 alpha-particles. The aim of this study was to develop approaches for stable and controlled targeting of (225)Ac to sites of disseminated tumor metastases. Liposomes with encapsulated (225)Ac were developed to retain the potentially toxic daughters at the tumor site. METHODS: (225)Ac was passively entrapped in liposomes. To experimentally test the retention of actinium and its daughters by the liposomes, the gamma-emissions of (213)Bi were measured in liposome fractions, which were separated from the parent liposome population and the free radionuclides, at different times. Under equilibrium conditions the decay rate of (213)Bi was used to determine the concentration of (225)Ac. Measurements of the kinetics of (213)Bi activity were performed to estimate the entrapment of (213)Bi, the last alpha-emitting daughter in the decay chain. RESULTS: Stable pegylated phosphatidylcholine-cholesterol liposomes of different sizes and charge were prepared. Multiple (more than 2) (225)Ac atoms were successfully entrapped per liposome. (225)Ac retention by zwitterionic liposomes was more than 88% over 30 d. Retention by cationic liposomes was lower. A theoretical calculation showed that for satisfactory (213)Bi retention (>50%), liposomes of relatively large sizes (>650 nm in diameter) are required. (213)Bi retention was experimentally verified to be liposome-size dependent. For large liposomes, the measured (213)Bi retention was lower than theoretically predicted (less than 10%). CONCLUSION: This work supports the hypothesis that it may be possible to develop (225)Ac-based therapies by delivering multiple (225)Ac atoms in liposomes. Improvements in the retention of (225)Ac daughters will likely be necessary to fulfill this potential. Because of the size of the liposomal structures required to contain the daughters, the approach is ideally suited for locoregional therapy (e.g., intraperitoneal, intrahepatic artery, or intrathecal).  (+info)

Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. (6/23)

The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mice at four hours after injection. All three bone-seeking agents showed a high uptake in bone and a low uptake in soft tissues. Among the soft tissue organs, only kidney had a relatively high uptake. The femur/kidney ratios for 227Th-DTMP, 228-Ac-DOTMP and 227Th-DOTMP were 14.2, 7.6 and 6.0, respectively. A higher liver uptake of 228Ac-DOTMP was seen than for 227Th-DTMP and 227Th-DOTMP. This suggests that some demetallation of the 228Ac-DOTMP complex had occurred. The results indicate that 225Ac-DOTMP, 227Th-DOTMP and 227Th-DTMP have promising properties as potential therapeutic bone-seeking agents.  (+info)

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. (7/23)

PURPOSE: The humanized monoclonal antibody, trastuzumab (Herceptin), directed against HER2/neu, has been effective in the treatment of breast cancer malignancies. However, clinical activity has depended on HER2/neu expression. Radiolabeled trastuzumab has been considered previously as a potential agent for radioimmunotherapy. The objective of this study was to investigate the efficacy of trastuzumab labeled with the alpha-particle emitting atomic generator, actinium-225 ((225)Ac), against breast cancer spheroids with different HER2/neu expression levels. (225)Ac has a 10-day half-life and a decay scheme yielding four alpha-particles. EXPERIMENTAL DESIGN: The breast carcinoma cell lines MCF7, MDA-MB-361 (MDA), and BT-474 (BT) with relative HER2/neu expression (by flow cytometry) of 1:4:18 were used. Spheroids of these cell lines were incubated with different concentrations of (225)Ac-trastuzumab, and spheroid growth was measured by light microscopy over a 50-day period. RESULTS: The activity concentration required to yield a 50% reduction in spheroid volume at day 35 was 18.1, 1.9, and 0.6 kBq/ml (490, 52, 14 nCi/ml) for MCF7, MDA, and BT spheroids, respectively. MCF7 spheroids continued growing but with a 20-30 day growth delay at 18.5 kBq/ml. MDA spheroid growth was delayed by 30-40 days at 3.7 kBq/ml; at 18.5 kBq/ml, 12 of 12 spheroids disaggregated after 70, days and cells remaining from each spheroid failed to form colonies within 2 weeks of being transferred to adherent dishes. Eight of 10 BT spheroids failed to regrow at 1.85 kBq/ml. All of the BT spheroids at activity concentrations 3.7 kBq/ml failed to regrow and to form colonies. The radiosensitivity of these three lines as spheroids was evaluated as the activity concentration required to reduce the treated to untreated spheroid volume ratio to 0.37, denoted DVR(37). An external beam radiosensitivity of 2 Gy was found for spheroids of all three of the cell lines. After alpha-particle irradiation a DVR(37) of 1.5, 3.0, and 2.0 kBq/ml was determined for MCF7, MDA, and BT, respectively. CONCLUSION: These studies suggest that (225)Ac-labeled trastuzumab may be a potent therapeutic agent against metastatic breast cancer cells exhibiting intermediate to high HER2/neu expression.  (+info)

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. (8/23)

Labeling of specific antibodies with bifunctional chelated Actinium-225 ((225)Ac; an alpha generator) allows the formation of new, highly potent and selective alpha-emitting anticancer drugs. We synthesized and evaluated a radioimmunoconjugate based on 3F8, an IgG(3) antibody that specifically binds to ganglioside GD2, which is overexpressed by many neuroectodermal tumors including neuroblastoma. The (225)Ac-1,4,7,10-tetra-azacylododecane (DOTA)-3F8 construct was evaluated for radiochemical purity and sterility, immunoreactivity, cytotoxicity in vitro, induction of apoptosis on GD2-positive cells, as well as for pharmacological biodistribution and metabolism of the (225)Ac generator and its daughters in a nude mouse xenograft model of neuroblastoma. The (225)Ac-3F8 showed an IC(50) of 3 Bq/ml (80 pCi/ml) on the neuroblastoma cell line, NMB7, in vitro. Apoptosis of these cells was not observed. Biodistribution in mice showed specific targeting of a subcutaneous tumor; there was redistribution of the (225)Ac daughter nuclides mainly from blood to kidneys and to small intestine. Toxicity was examined in cynomolgus monkeys. Monkeys injected with 1 to 3 doses of intrathecal (225)Ac-3F8 radioimmunoconjugate (80 to 150 kBq/kg total dose) did not show signs of toxicity based on blood chemistry, complete blood counts, or by clinical evaluations. Therapeutic efficacy of intrathecal (225)Ac-3F8 was studied in a nude rat xenograft model of meningeal carcinomatosis. The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis.  (+info)

NEW YORK, NY--(Marketwired - October 13, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (Actinium or the Company) is a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Steve OLoughlin to the position of Senior Director of Finance and...
From BioPortfolio: NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutica...
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a phase I trial, in which a preset schedule of doses gets more powerful for each new group of patients as the trial progresses. If too many serious side effects are seen with a certain dose, no one will be treated with a higher dose, and some additional patients may be treated with a lower dose to make sure that this dose is safe. The starting dose of actinium-225 in this study is less than doses that are known to be safe in animals.. Antibodies are proteins that are produced by the immune system and help the body to fight foreign substances, such as bacteria or viruses. HuM195 was made by putting human leukemia cells into mice. Most of the mouse parts of this antibody were replaced with human parts. Only the part of the antibody that binds to the leukemia cells was kept from the mouse. HuM195 attaches to leukemia cells but does not attach to most normal cells. It can kill ...
Combining traditional textiles with triboelectric nanogenerators (TENGs) gives birth to self-powered electronic textiles (e-textiles). However, there are two bottlenecks in their widespread application, low power output and poor sensing capability. Herein, by means of the three-dimensional five-directional braided (3DB) structure, a TENG-based e-textile with the features of high flexibility, shape adaptability, structural integrity, cyclic washability, and superior mechanical stability, is designed for power and sensing. Due to the spatial frame-column structure formed between the outer braided yarn and inner axial yarn, the 3DB-TENG is also endowed with high compression resilience, enhanced power output, improved pressure sensitivity, and vibrational energy harvesting ability, which can power miniature wearable electronics and respond to tiny weight variations. Furthermore, an intelligent shoe and an identity recognition carpet are demonstrated to verify its performance. This study hopes to provide a
Triboelectric nanogenerators (TENG) convert mechanical energy harvested from the environment to electricity for powering small devices such as sensors or for recharging consumer electronics. Now, researchers have harnessed ...
For the first time, fully bio-derived thermosets have been synthesized from abundantly available, low cost, renewable feedstocks through a simple, solvent-free and catalytic process for the fabrication of triboelectric nanogenerators (TENGs) for sustainable power generation. Thermoset films synthesized from
X-ray Research on Short-lived Isotope Provides New Possibilities for Cancer Treatment - Scientists Improve Understanding of Mysterious Actinium. Excerpted from August 22, 2016 SLAC News Feature. A recent paper published in Nature Communications reveals insights about the element actinium that could support new classes of anticancer drugs. A team of researchers from the Los Alamos National Laboratory has conducted x-ray absorption fine structure experiments on SSRLs Beam Line 11-2 to characterize the molecular and electronic structure, including chemical bonds in actinium compounds.. Using synchrotron-based tools to obtain a better understanding of the structure of Actinium-225, for example, looks promising. It has a relatively short half-life (10 days) and emits powerful alpha particles as it decays to stable bismuth. This makes it a perfect candidate for a novel cancer treatment technique called targeted-alpha therapy, where alpha emissions from radioisotopes destroy malignant cells while ...
A chemical element, Ac, atomic number 89, and atomic weight 227.0. Actinium was discovered by A. Debierne in 1899. Milligram quantities ...
NEW YORK, NY--(Marketwired - March 11, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (Actinium or the Company), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has engaged a leading European-based regulatory affairs consulting firm to pursue orphan medicines designation...
Blue line and other details for Actinium Delight Minor. Classification: Delight Minor, Place Notation: x56x1456x1256x16.34x34.56,12
ATNM - key executives, insider trading, ownership, revenue and average growth rates. Detailed company description & address for Actinium Pharmaceuticals Inc..
Selective chelation of bismuth radionuclide ions from a mixture including actinium radionuclide ions involves exposing a ligand to an aqueous solution that includes bismuth radionuclide ions and actinium radionuclide ions under conditions whereby the bismuth radionuclide ions selectively chelate to the ligand for form cationic complexes of the bismuth radionuclide ions. and separating the cationic complexes of the bismuth radionuclide ions from the actinium radionuclide ions. The ligands have a structure based on a 12-membered cyclen ring and may include pendant functional groups that can be derivatized with biological targeting vectors for targeted alpha therapy.
It is necessary to construct an amphiphobic triboelectric nanogenerator (TENG) since water, oil and other antistatic agents will have a great impact on its electrical output performance during practical applications. Herein, we put forward a high-performance TENG based on silica enhanced thermoplastic polymeric nan
Since cellulose is non-toxic, the researchers said the device could potentially be implanted in the body and harvest its internal stretches, vibrations and other movements.
Das Periodensystem der Elemente kurz, prägnat, übersichtlich. Die wichtigsten Infos schnell parat. Mit interaktiver Nuklidkarte inklusive.
Equities.com is an advanced financial information center and next-generation communication platform that connects self-directed investors with startup and small cap companies, market experts, and professional service providers and vendors.
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the pl...
Equities.com is an advanced financial information center and next-generation communication platform that connects self-directed investors with startup and small cap companies, market experts, and professional service providers and vendors.
۲٫۰ ۲٫۱ ۲٫۲ Kirby, Harold W.; Morss, Lester R. (2006). [اصطلاحي تېروتنه: د ناپېژندلې ليکنښې لوښه ۱. "Actinium"]. The Chemistry of the Actinide and Transactinide Elements. pp. 18. doi:10.1007/1-4020-3598-5_2. ISBN 978-1-4020-3555-5. ...
Further analyses of data subsets from the ALSYMPCA study of the alpha particle-emitting isotope Ra-223 (Xofigo) were presented at ASCO, providing additional evidence of efficacy and safety of the recently FDA approved therapeutic agent.
CSIC through the Instituto de Microelectrónica de Barcelona - Centro Nacional de Microelectrónica, has developed a device based on nanogenerators for electrical cells stimulation without the need of electrodes or bulky devices. The device is biocompatible and, among its multiple applications, is able to actuate in medical prostheses as an enhancer of cellular growth and proliferation, which permits an early lesion recovery (such as a fracture or wound). Industrial partners dedicated to the development of medical devices for cells stimulation, in particular, focused onto therapeutic treatments of non-healing wounds, are being sought to collaborate through a patent license agreement.
Researchers at Georgia Tech have been working on the prototypes for six years and say that if placed in the perfect arrangement within layers of polymer material, they could be flexed to generate and capture electricity.. The chips are roughly a quarter of the size of a postage stamp. Stack five of them on top of each other and they can be used to generate the same voltage as two AA batteries. This can be produced simply by squeezing them together with your fingertips.. "Additional nanowires and more nanogenerators, stacked together, could produce enough energy for powering larger electronics, such as an iPod or charging a cell phone." said Zhong Lin Wang, who heads up the research.. In a presentation at an American Chemical Society meeting in California, Wang said the device is 150 times more powerful than early prototypes.. "This development represents a milestone toward producing portable electronics that can be powered by body movements without the use of batteries or electrical outlets… ...
Some teams have significantly accelerated the proliferation and differentiation of mouse embryonic bone-forming cells when using a so-called triboelectric nanogenerator. An electric current is generated when two materials are separated and then brought back into contact. These nanogenerators have been tested with materials such as polydimethylsiloxane, indiumtin oxide, aluminium, and polytetrafluoroethylene. They are showing potential for treating osteoporosis and osteoporosis-related fractures ...
The following is a listing of the USEPAs dose conversion factors for inhalation of some commonly-encountered radionuclides. The values shown below are in units of "millirem per microcurie inhaled", and may be used to convert estimates of intake into committed effective dose equivalent. Included as well is a notation showing the applicable lung clearance class (i.e., Y = years, W = weeks, and D = days).. Actinium. ...
Actinium Pharmaceuticals says that exposing venetoclax-resistant AML cells to a CD33-targeted antibody radionuclide conjugate may resensitize cells to the drug and improve patient outcomes.
Protons Neutrons And Electrons For Helium - 28 images - Diagram Of The Atom Model Wedocable, How Are Elements Broken Into Protons Electrons And, Helium Atom Stock Photos Helium Atom Stock Images Alamy, Basic Chemistry Tutorial 2 Drawing Atoms Sciencemusicvideos, Element Diagram Of Helium Diagram Of Actinium Element
The product will be able to reduce redness and unevenness of complexion also. Should be easy to purchase If driving down to the drugstore every couple of days to purchase a new jar of the product is difficult, you should be able to obtain it home delivered then. A number of these products may be ordered on-line. Some products even provide a 30 day without risk trial to be able to try services at your leisure. It is created by This list easy for you to decide which products you require. Having the right age defying face creams ensures that you can start your skincare program as soon as possible.. 3 Criteria For FINDING THE RIGHT Anti Wrinkle Face Creams Are you noticing the first appearance of lines or wrinkles on your forehead or around the corners of your eye? Wrinkles are associated with advanced age group.His research passions include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, development of novel ...
Late-onset Alzheimers disease (AD) accounts for the majority of AD cases. A characteristic feature of AD is the accumulation of β-amyloid (Aβ) plaques in the brain. Several mutations are associated with risk for late-onset AD, particularly mutations in the genes encoding apolipoproteins APOE4 and clusterin (also known as APOJ), which alter the metabolism and impair the clearance of Aβ. Mutations in the gene encoding TREM2 (triggering receptor expressed on myeloid cells 2), a protein with a single transmembrane domain that is present in microglia in the brain, are also associated with increased risk of AD. Yeh et al. found that the three risk factors are mechanistically linked. A protein microarray screen using a library of secreted ligands immobilized on glass slides and a fusion antibody construct containing the extracellular domain of TREM2 or TREM1 identified various lipoproteins as potential selective ligands of TREM2. These included low-density lipoprotein, lipidated APOE and lapidated ...
The encouraging preclinical results have led to the initiation of a clinical development program for 223RaCl2. Approval was obtained from the applicable institutional review boards, and all patients provided informed written consent before entering the clinical studies.. Phase 1A. A phase 1 study of single-dosage administration of escalating amounts of 223Ra in 25 patients with bone metastases from breast and prostate cancer was recently published (44). Dose-limiting hematologic toxicity was not observed. Dosages of 46, 93, 163, 213, or 250 kBq/kg were applied. Mild and reversible myelosuppression occurred with only grade 1 toxicity for thrombocytes at the two highest dose levels. Quality of life was evaluated at baseline and at 1, 4, and 8 weeks after injection, respectively. Pain relief was observed for all time points in ,50% of the patients. Furthermore, a decline in total serum alkaline phosphatase ,50%, accepted as a prognostic marker in metastatic prostate cancer, was observed among ...
By combining a new generation of piezoelectric nanogenerators with two types of nanowire sensors, researchers have created what are believed to be the first self-powered nanometer-scale sensing devices that draw power from the conversion of mechanical energy.
NEW YORK, Sept. 28, 2016-- Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it intends to offer shares of its common stock in an underwritten public offering. A preliminary prospectus supplement and accompanying prospectus...
for treating castration resistant prostate cancer and symptomatic bone metastases. From the website below: "The active moiety of Xofigo is the alpha particle-emitting isotope radium 223 (as radium 223 dichloride), which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium 223 dichloride is less than 100 micrometers (less than 10 cell diameters) which limits damage to the surrounding normal tissue. After intravenous injection, radium 223 is rapidly cleared from the blood and is distributed primarily into bone or is excreted into intestine. Fifteen minutes post-injection, about 20% of the injected radioactivity remained in blood. At 4 hours, about 4% of the injected radioactivity remained ...
Class: Radiopharmaceutical. Generic Name: Radium Ra 223 dichloride (RAY-dee-um Ra 223 dye-KLOR-ide). Trade Name: Xofigo®. For which conditions is this drug approved? Radium Ra 223 dichloride is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.. What is the mechanism of action? The active component of radium Ra 223 dichloride is the alpha particle-emitting isotope radium-223 (as radium Ra 223 dichloride), which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium-223 dichloride is less than 100 micrometers (less than 10 cell diameters), which limits damage to the surrounding normal ...
Bispecific T cell engager (BiTE®) antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the bodys immune system to detect and target malignant cells. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. BiTE® antibody constructs help place the T cells within reach of the targeted cell, with the intent of allowing T cells to inject toxins and trigger the cancer cell to die (apoptosis). BiTE® antibody constructs are currently being investigated for their potential to treat a wide variety of cancers. For more information, visit www.biteantibodies.com.. About ...
In generating energy from movement, Wang says his team concluded that it was most effective to develop a method that worked at low frequencies and was based on flexible materials. The ZnO nanowires met these requirements. At the same time, he says a real advantage of this technology is that the nanowires can be grown easily on a wide variety of surfaces, and the nanogenerators will operate in the air or in liquids once properly packaged. Among the surfaces on which the nanowires can be grown are metals, ceramics, polymers, clothing and even tents ...
Two aspects of the radionuclide source terms used for total-system performance assessment (TSPA) analyses have been reviewed. First, a detailed radionuclide inventory (i.e., one in which the reactor type, decay, and burnup are specified) is compared with the standard source-term inventory used in prior analyses. The latter assumes a fixed ratio of pressurized-water reactor (PWR) to boiling-water reactor (BWR) spent fuel, at specific amounts of burnup and at 10-year decay. TSPA analyses have been used to compare the simplified source term with the detailed one. The TSPA-91 analyses did not show a significant difference between the source terms. Second, the radionuclides used in source terms for TSPA aqueous-transport analyses have been reviewed to select ones that are representative of the entire inventory. It is recommended that two actinide decay chains be included (the 4n+2 ``uranium`` and 4n+3 ``actinium`` decay series), since these include several radionuclides that have potentially important
Alpha particles are emitted mainly by the heaviest of the isotopes (e.g., all elements above bismuth (Bi-209) are radioactive, and most are alpha particle emitters. These nuclei are too big to be stable and decay by emitting an alpha particle. Very often the resulting nucleus, called a "Daughter nucleus", is also too big and unstable. It too usually emits an alpha particle. This process can happen a number of times depending upon the starting isotope and the ultimate stable isotope. The stable isotope of the alpha emitters is usually lead (the element just below Bismuth, and has 4 stable isotopes for the "Decay Chains" to stop on). For example, the most abundant isotope of uranium, U-238, it takes the emission of 5 alpha particles to get to stable lead.. Alpha particles are high speed helium atoms without electrons. Consisting of a nucleus of 2 protons and 2 neutrons, this is the largest common (naturally occurring) radiation particle. Since there are no electrons, the alpha particle is highly ...
The data suggest that alpha-particle immunotherapy to neovasculature, alone or in combination with sequential chemotherapy, is an effective approach to cancer therapy.
Resonances in the yield of ground-state protons from alpha-particle bombardment of 31P were investigated in the energy range Eα = 1.7 − 3.3 MeV. Fourteen resonances were observed, none of which was known before. Resonance energies and strengths are presented. Angular distribution measurements lead to unique values of the resonance ... read more spin in all cases but one. The exception is the strong resonance at Eα = 3.302 MeV, which shows a deviation from forward-backward symmetry in the angular distribution, to be explained by assuming interference with some unknown broad resonance(s) with opposite parity, probably at higher energy. show less ...
Measured alpha particle hits per unit tumour area per 1 hour for two groups of tumour sections: 4 sections with and 3 sections without application of chemothera
Get an answer for Alpha radiation is a strong ionizer, but it can only penetrate through few cm of air. How then can alpha particles cause human biological damage? and find homework help for other Science questions at eNotes
This is a single-arm, single-site pilot of Radium-223 (55 kBq/kg) IV q3 weeks for up to 6 doses in combination with Atezolizumab 1200mg IV once every 3 weeks
The larger and more charged the radiation the more ionizations occur. Alpha particles are very highly ionizing, thus would have a larger LET than a low energy gamma. Alpha particles will cause more biological damage in a very small area ...
Asylum Research will sponsor a free atomic force microscopy (AFM) Workshop on February 12 and 13, 2009 in the Pettit Building/Microelectronics Research Center (MiRC) on the Georgia Institute of Technology (Georgia Tech) campus. The Workshop will include three keynote talks by Georgia Tech researchers on Nanogenerators (Dr. Jinhui Song), on Heterogeneous Lipoprotein Assembly and Structure (Dr. Todd Shulchek), and on Microgels on Surfaces (Dr. Toni South). Asylum Research scientists Dr. Nick Geisse and Keith Jones will speak on AFM instrument technology and combined AFM and Optical Imaging. The first day of the workshop will include the talks described above, as well as an afternoon AFM demonstration session on the MFP-3D-BIO AFM. The second day of the workshop will continue with in-depth AFM applications demonstrations. Lunch will be provided on the 12th. The Workshop is open to all researchers and students; seating is limited and all attendees must pre-register. Full details on the workshop, as ...
Wearable and implantable electronics (WIEs) are more and more important and attractive to the public, and they have had positive influences on all aspects of our lives. As a bridge between wearable electronics and their surrounding environment and users, sensors are core components of WIEs and determine the implementation of their many functions. Although the existing sensor technology has evolved to a very advanced level with the rapid progress of advanced materials and nanotechnology, most of them still need external power supply, like batteries, which could cause problems that are difficult to track, recycle, and miniaturize, as well as possible environmental pollution and health hazards. In the past decades, based upon piezoelectric, pyroelectric, and triboelectric effect, various kinds of nanogenerators (NGs) were proposed which are capable of responding to a variety of mechanical movements, such as breeze, body drive, muscle stretch, sound/ultrasound, noise, mechanical vibration, and blood flow,
Chemistry (from Egyptian kēme (chem), meaning "earth") is the physical science concerned with the composition, structure, and properties of matter, as well as the changes it undergoes during chemical reactions. Below is a list of chemistry-related articles. Chemical compounds are listed separately at list of organic compounds, list of inorganic compounds or list of biomolecules. Contents A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Abichite Acetaldehyde Acetaminophen Acetic acid Acetone acetyl Acetylcholine Acetylene acid Acrylamide Actinide Actinium Actinolite Activation energy Adolf Friedrich Johann Butenandt Adolf Otto Reinhold Windaus Adolph Wilhelm Hermann Kolbe Agate Ahmed H. Zewail Alabaster Alan G MacDiarmid Alan J Heeger Albertus Magnus Albite alchemical symbol alchemist Alchemy alcohol aldehyde Alexandrite Alfred Stock Alfred Werner alicyclic compound aliphatic compound Alkali Alkali metal Alkaline earth alkane alkene Allingite allotrope Allotropy alloy Alum Aluminium Aluminium ...
A list of 8 letter words that end with m in the enable uncensored word list. (518 words: abomasum accustom aciculum aconitum acrotism actinism actinium activism addendum aecidium aeriform aerobium aerogram ageratum alarmism albinism alburnum algorism alienism allelism...)
Words Ending In um: abomasum,acaridomatium,acarodomatium,acetabulum,acetum,achaenium,achenium,aciculum,aconitum,acroterium,actinium,actinouranium,addendum,adsum,adytum,aecidium,aecium,aerobium,agendum,ageratum,alarum,alb
Radium-223. Radium-223 is a bone-targeted, alpha-emitting radiopharmaceutical that was FDA-approved in 2013 for the treatment of patients with mCRPC. Radium (Ra), like calcium (Ca), strontium (Sr), and barium (Ba), is an alkaline earth metal in the periodic table of the elements, which, as a family, localize to areas of osteoblastic metastasis. The FDA approval came from the results of ALSYMPCA,17 a phase III trial in which 921 patients received radium-223 or placebo, and all patients received SOC. SOC was confined to nonchemotherapeutics and older hormonal therapies such as flutamide, bicalutamide, and dexamethasone. Enzalutamide and abiraterone were not yet approved when the phase III study was performed. Patients received a total of 6 injections, each of which was administered at 4-week intervals at a dosage of 50kBq/kg. The becquerel (Bq) is an SI unit for radioactivity defined as the activity of a quantity of radioactive material in which 1 nucleus decays per second.. The primary endpoint ...
Summary of Facts and Submissions. I. Appeal lies from the decision of the examining division to refuse the European patent application No. 04739378.0, entitled Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders.. II. The examining division considered a main request and an auxiliary request and held that the subject-matter of claim 1 of both lacked inventive step.. III. With the statement of grounds of appeal the appellant submitted a main and two auxiliary requests.. IV. The board issued a communication pursuant to Article 15(1) RPBA, in which objections inter alia under Articles 56 and 84 EPC were raised by the board (Article 111(1) EPC).. V. In reply, the appellant submitted a letter dated 30 August 2016, accompanied by a new main request, and renumbered the previous main request as auxiliary request 3. The appellant later informed the board that he would not be represented at the oral proceedings.. VI. Oral ...
"89 Actinium". Elements.vanderkrogt.net. Retrieved 2008-09-12.. *^ Kirby, Harold W. (1971). "The Discovery of Actinium". Isis. ... Actinium 1902 F. O. Giesel 1902 F. O. Giesel Giesel obtained from pitchblende a substance that had properties similar to those ... of lanthanum and named it emanium.[120] André-Louis Debierne had previously reported the discovery of a new element actinium ...
actinium 89 Ac thorium 90 Th protactinium 91 Pa uranium 92 U ...
Actin-ium89Ac​[227] Ruther-fordium104Rf​[267] Dub-nium105Db​[268] Sea-borgium106Sg​[269] Bohr-ium107Bh​[270] Has-sium108Hs​[269 ...
Actinium C. 81. 126. 206.977419(6). 4.77(2) min. β−. 207Pb. 1/2+. Trace[n 8]. ...
Actinium seriesEdit. The 4n+3 chain of uranium-235 is commonly called the "actinium series" or "actinium cascade". Beginning ... Actinium A α 99.99977% β− 0.00023% 1.781 ms 7.527 0.715 211Pb 215At ... Actinium C α 99.724% β− 0.276% 2.14 min 6.751 0.575 207Tl 211Po ... Actinium β− 98.62% α 1.38% 21.772 a 0.045 5.042 227Th 223Fr ... Actinium C' α 516 ms 7.595 207Pb 207Tl AcC" Actinium C" β−. ...
Actin-ium89Ac​[227] Ruther-fordium104Rf​[267] Dub-nium105Db​[268] Sea-borgium106Sg​[269] Bohr-ium107Bh​[270] Has-sium108Hs​[270 ... Lanthanum and actinium. La and Ac below Y Lanthanum and actinium are commonly depicted as the remaining group 3 members.[138][n ... Actinium Thorium Protactinium Uranium Neptunium Plutonium Americium Curium Berkelium Californium Einsteinium Fermium ... Actinium Thorium Protactinium Uranium Neptunium Plutonium Americium Curium Berkelium Californium Einsteinium Fermium ...
He was aware of the discovery of actinium by André-Louis Debierne. In publications from 1899 and 1890 Debierne does not give ... In a now controversially reviewed process it was stated that emanium is identical to actinium, which was discovered by André- ... Giesel, on the other hand, can rightfully be credited with the first preparation of radiochemically pure actinium and with the ... Kirby, H. W. (1971). "The Discovery of Actinium". Isis. 62 (3): 290-308. doi:10.1086/350760. JSTOR 229943. Giesel, F. (1900). " ...
... actinium Rehder, 1980. Retrieved through: World Register of Marine Species on 17 May 2010. Cerithidium australiense ... Cerithidium actinium Rehder, 1980 Cerithidium australiense Thiele, 1930 Cerithidium cerithinum (Philippi, 1849) Cerithidium ...
This research resulted in the successful identification of a new element in the decay chain between uranium-235 and actinium, ... Soddy, F.; Cranston, J. A. (1 June 1918). "The Parent of Actinium". Proceedings of the Royal Society A: Mathematical, Physical ... on the possible modes of origin of actinium. With regard to the new work, in the absence of one of us on military service since ...
In 1899, he discovered the radioactive element actinium, as a result of continuing the work with pitchblende that the Curies ... H. W. Kirby (1971). "The Discovery of Actinium". Isis. 62 (3): 290-308. doi:10.1086/350760. JSTOR 229943. ESPCI ParisTech ... was a French chemist and is considered the discoverer of the element actinium. Debierne studied at the elite École supérieure ...
89 Ac actinium (Ac-227 ?) use. 3471 K. 3198 °C. 5788 °F ...
Passiflora actinia Hook. Passiflora alata Dryand. Passiflora amethystina J.C.Mikan Passiflora deidamioides Harms Passiflora ...
Actinium. Glenn T. Seaborgs model for fremtidige grundstoffer:. 7. 1. 8. 7p. Ununtrium. ...
Alt: Quartz vial (9 mm diameter) containing ~300 micrograms of solid 253Es. The illumination produced is a result of the intense radiation from 253Es ...
Actinium is discovered by Andre-Louis Debierne. International Committee on Atomic Weights established. January 23 - The British ...
Actinia fragacea is similar in form to the beadlet anemone (Actinia equina) and was at one time considered to be a variant of ... The strawberry anemone (Actinia fragacea) is an Anthozoan of the order Actiniaria, a sea anemone, that occurs from Norway to ... 113-. ISBN 978-94-011-5888-6. "Strawberry anemone - Actinia fragacea". MarLIN. Retrieved 2015-08-18. Encyclopedia of Marine ...
Actinia equina is similar in form to the Waratah anemone (Actinia tenebrosa) of Australia and New Zealand. It is also similar ... The beadlet anemone, Actinia equina, is a common sea anemone found on rocky shores around all coasts of the United Kingdom and ... Actinia equina can be found both in exposed and sheltered situations. It is highly adapted to the intertidal zone as it can ... Actinia equina is viviparous, with up to one hundred embryos developing inside the body cavity before being ejected into the ...
A further study in 2000 concluded that Actinia priapus; Tilesius, 1809, Actinia farcimen; Brandt, 1835, and Isometridium ... Of these, Actinia farcimen was the name first published. It is, however, a junior homonym so the valid name for the species is ...
Cotelle "collaborated with Curie on studies of actinium. With Curie she redetermined the half life of ionium using a method ...
Eighty-nine is: The atomic number of actinium. Messier object M89, a magnitude 11.5 elliptical galaxy in the constellation ...
Secondary decay products of thorium include radium and actinium. Because of this, there are concerns about the safety of ...
Actinium Thorium Protactinium Uranium Neptunium Plutonium Americium Curium Berkelium Californium Einsteinium Fermium ... The fourth element, either actinium or lawrencium, has only radioactive isotopes. Actinium, which occurs only in trace amounts ... Actinium (Ac*). 89 Actinide * Whether the elements lutetium (Lu) and lawrencium (Lr), in period 6 and 7, are in group 3 is ... Scandium (Sc) and yttrium (Y) are always included, but the other two spaces are usually occupied by lanthanum (La) and actinium ...
Proto- (from Greek prôtos, 'first, before') + actinium, since actinium is produced through the radioactive decay of ... Actinium. Greek aktís, 'ray'. 3. 7. [227][IX]. 10.07. 1323. 3471. 0.12. 1.1. 5.5×10−10[X]. ...
actinium 499. 1170. 1900. 4700 90. Th. thorium 587. 1110. 1978. 2780 ...
"The Actinium Series and the Lead Ratios in Rocks." Nature 117 (1926): 719-720. doi:10.1038/117719b0 with W. M. Rayton: " ...
Passiflora actinia. Passiflora actinia. Passiflora alata. Fragrant Granadilla. Passiflora biflora. Two-Flowered Passion Flower ...
Passiflora bicuspidata is a rare delicate mountain species from Colombia that produces beautiful crimson red flowers. Fabulous plant.
Overview Actinium is the third element in Row 7 of the periodic table [1], a chart that shows how the chemical elements are ... ACTINIUM (REVISED) Note: This article, originally published in 1998, was updated in 2006 for the eBook edition. ... About a dozen isotopes of actinium are known. All are radioactive. The two that occur in nature are actinium-227 and actinium- ... Actinium Chemistry: Foundations and Applications COPYRIGHT 2004 The Gale Group, Inc.. Actinium. melting point: 1,050°C. boiling ...
... tenebrosa Farquhar 1898. Please note: Entries in the above species list are the original binomina of species according ... Actinia Click on an image to view larger version & data in a new window ... Actinia. Version 01 January 2000 (temporary). http://tolweb.org/Actinia/18342/2000.01.01 in The Tree of Life Web Project, http ...
Periodic Table of the Elements: Actinium. Periodic Table of the Elements: Actinium. Atomic Number:. 89. ...
The isotopes of actinium range in atomic weight from 206 u (206 Ac) to 236 u (236 Ac). Actinium is found only in traces in ... Actinium gave the name to the actinide series, a group of 15 similar elements between actinium and lawrencium in the periodic ... The actinium isotope 227Ac is a transient member of the uranium-actinium series decay chain, which begins with the parent ... Actinium metal has been prepared by the reduction of actinium fluoride with lithium vapor in vacuum at a temperature between ...
Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the ... About Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical ... NEW YORK, NY--(Marketwired - June 04, 2015) - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT: ATNM), a ... Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, ...
Actinium fluoride (AcF3) is an inorganic compound of actinium and fluorine. Actinium fluoride can be prepared in solution or by ... Actinium fluoride is a white solid that reacts with ammonia at 900-1000 °C to yield an actinium oxyfluoride: A c F 3 + 2 N H 3 ... In the first method, actinium hydroxide is treated with hydrofluoric acid and the product precipitates: A c ( O H ) 3 + 3 H F ... Haire, Richard G. (2006). "Actinium". In Morss; Edelstein, Norman M.; Fuger, Jean. The Chemistry of the Actinide and ...
6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative ... About Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that ... Jack Talley, Actiniums President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference on Monday, February ... Forward-Looking Statement for Actinium Pharmaceuticals, Inc.. This news release contains forward-looking statements as that ...
This WebElements periodic table page contains properties of free atoms for the element actinium ... The ionisation energies of actinium are given below.. Ionisation energies of actinium. Ionisation energy number. Enthalpy / kJ ... A representation of the atomic spectrum of actinium.. Electronic configuration of neutral atomic actinium The electronic ... The ground state electron configuration of ground state gaseous neutral actinium is [Rn].6d1.7s2 and the term symbol is 2D3/2. ...
The Department of Energys Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a ... ORNL increases production of actinium-227 to meet demand for cancer drug. *Download PDF Copy ... The Department of Energys Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a ...
PRNewswire/ -- Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle ... About Actinium 225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium ... About Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. is a Newark, New Jersey based biopharmaceutical company that ... Actinium Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A™ Actiniums ...
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations September 06, 2018 ... Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease ... Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting August 14, 2018 ... Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions September 04 ...
NEW YORK, NY--(January 11, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company ... Actinium Pharmaceuticals to Present at Biotech Showcase 2016 Press Releases Follow , Monday, 11 January 2016 10:07 (EST). Live ... Actinium Pharmaceuticals, Inc. [email protected] DISCLOSURE: The views and opinions expressed in this article are ... Actiniums management will host one-on-one meetings with conference attendees at Biotech Showcase 2016, which can be scheduled ...
NASDAQ: ATHX), Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM), and AVEO Pharmaceuticals ... Actinium Pharma Shares in New York-based Actinium Pharmaceuticals Inc. recorded a trading volume of 155,920 shares. The stock ... Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma. Friday, May 19, 2017 Drug ... On May 17th, 2017, Actinium Pharma announced that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the ...
This investigation is a bioprospecting study that aims to isolate and identify protease inhibitors from the cnidarian Actinia ... Actinia tenebrosa, kallikrein-related peptidases, Kunitz inhibitor, serine protease, mass spectrometry imaging, molecular ... A Versatile and Robust Serine Protease Inhibitor Scaffold from Actinia tenebrosa. Chen, Xingchen ...
Neoplasms Metastasis Completed Phase 3 Trials for Actinium (DB12860). Back to Neoplasms Metastasis ...
... Research Article: NorthStar Perspectives for Actinium- ... Actinium-225 and Bismuth-213 are used in AIT However, both of these isotopes have low production yields and their production ... Harvey summarizes the importance of new techniques required to produce larger quantities of Actinium and presents the ... This is followed by details of established and experimental methods of Actinium production. ...
CELL BY CELL is a trademark and brand of Actinium Pharmaceuticals, Inc.. Filed to USPTO On Friday, January 19, 2001, The ... This is a brand page for the FIGHTING CANCER, CELL BY CELL trademark by Actinium Pharmaceuticals, Inc. in Alexandria, , 22314. ... On Friday, January 19, 2001, a U.S. federal trademark registration was filed for FIGHTING CANCER, CELL BY CELL by Actinium ... Actinium Pharmaceuticals, Inc.. Alexandria 22314 Why is this contact information displayed? Why is this contact information ...
View Name Sources Download CSV Download BibTeX Bibliography for Actinia bicolor by Page ...
About Actinium Pharmaceuticals, Inc.. Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to ... The AWE technology enables Actiniums internal pipeline and with the radioisotope Actinium-225 is being utilized in a ... Actinium Pharmaceuticals, Inc. Steve OLoughlin. Principal Financial Officer. [email protected] Investor Relations ... Actiniums Iomab-ACT program is an expansion of its CD45 program that is intended to be a universal, chemotherapy-free solution ...
Actinia explanation. Define Actinia by Websters Dictionary, WordNet Lexical Database, Dictionary of Computing, Legal ... Actinia - a genus of sea anemone common in rock pools. Synonyms: genus Actinia ... Actinia Ac`tin´i`a. n.. 1.. (Zool.) An animal of the class Anthozoa, and family Actinidæ. . From a resemblance to flowers in ... Actinaria, Actiniaria, coelenterate genus, genus Actinia, order Actinaria, order Actiniaria. Translate Actinia to French ...
Actinium Pharmaceuticals, Inc. (ATNM) - Frigate Ventures LP has filed a new SC 13G, reporting a 5.50% ownership stake in ... Actinium Pharmaceuticals, Inc. (ATNM) and SCYNEXIS, Inc. (SCYX) Activist Update. March 13, 2018 at 9:30 pm. by Fintel ... Actinium Pharmaceuticals, Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations ... disclosing ownership of 6,000,000 shares of Actinium Pharmaceuticals, Inc. (AMEX:ATNM). This represents 5.5 percent ownership ...
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a phase ... Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 A single infusion of 225Ac-HuM195 will be ... The starting dose of actinium-225 in this study is less than doses that are known to be safe in animals. ... Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 Phase 1 ...
Actinium-225 gives off high-energy alpha particles as it decays, which kill cancer cells and as actinium-225 decays it produces ... About Actinium Pharmaceuticals, Inc.. Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on ... 11, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced ... More articles issued by Actinium Pharmaceuticals. More articles related to:. Company Announcement Calendar of Events Product / ...
  • Actinium is found only in traces in uranium and thorium ores as the isotope 227Ac, which decays with a half-life of 21.772 years, predominantly emitting beta and sometimes alpha particles, and 228Ac, which is beta active with a half-life of 6.15 hours. (wikipedia.org)
  • One tonne of natural uranium in ore contains about 0.2 milligrams of actinium-227, and one tonne of natural thorium contains about 5 nanograms of actinium-228. (wikipedia.org)
  • NEWARK, N.J. , July 19, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A™ in Acute Myeloid Leukemia (AML) clinical trial. (prnewswire.com)
  • Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. (yahoo.com)
  • Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. (prnewswire.com)
  • Actinium-225 and Bismuth-213 are used in AIT However, both of these isotopes have low production yields and their production currently doesn't match the scales of their consumption in medical processes. (benthamscience.com)
  • Actinium Pharmaceuticals is engaged in the development and commercialization of alpha particle immunotherapeutics based on a unique patent position for the utilization of actinium-225 and bismuth-213. (thefreedictionary.com)
  • Significant research has been done in the separation of the alpha emitter Bismuth-213 from its parent solution of Actinium-225 using organic resins. (tennessee.edu)
  • Due to radiolytic damage to the resin emphasis in the research has focused on the rapid elution of Bismuth-213 or storage of the parent Actinium-225 solution on a more robust resin. (tennessee.edu)
  • If an inorganic resin could retain its structural integrity then Actinium-225 could be loaded on an inorganic resin bed with a clinical dose of Bismuth-213 eluted from the column when needed. (tennessee.edu)
  • The performance of two inorganic ion exchange resins, Isolute SCX and Isolute SCX-2, were compared to the performance of the organic resin AG-50X8 in the separation of the radionuclide Bismuth-213 from its parent solution of Actinium-225. (tennessee.edu)
  • Performance was based on the percent of Bismuth-213 available eluted, and the breakthrough of Actinium-225. (tennessee.edu)
  • Moore, Mark Alan, "The Separation of Bismuth-213 from Actinium-225 and the Ion Exchange Properties of the Alkali Metal Cations with an Inorganic Resin. (tennessee.edu)
  • Actinium formally introduced its Iomab-ACT program on September 26th, 2018 via a webcast in conjunction with the Froedtert and Medical College of Wisconsin, a leading CAR-T and FACT accredited medical institution that is working with the company on clinical advancement of the program. (pharmiweb.com)
  • The name actinium originates from the Ancient Greek aktis, aktinos (ακτίς, ακτίνος), meaning beam or ray. (wikipedia.org)
  • As we continue to achieve our stated milestones, completion of the first cohort brought us another step closer to the Phase II portion of the trial,' said Dr. Dragan Cicic , the CEO of Actinium Pharmaceuticals. (prnewswire.com)
  • Actinium Pharmaceuticals announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 American Society of Clinical Oncology Annual Meeting held from May 31st-June 4th in Chicago. (thefreedictionary.com)
  • With Iomab-B poised to enter a pivotal Phase 3 trial, Actimab-A moving towards a Phase 2 trial and an ever strengthening team it is an honor to join Actinium at such a momentous time for the Company. (marketwired.com)
  • On May 17 th , 2017, Actinium Pharma announced that Dr. Richard Stone , Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School , has joined the Company's Scientific Advisory Board (SAB). (medindia.net)
  • Actinium announced today the appointment of Steve O'Loughlin to the position of Senior Director of Finance and Corporate Development. (marketwired.com)
  • I am very excited to join the Actinium team and eager to assume my responsibilities," said Mr. O'Loughlin. (marketwired.com)
  • I look forward to leveraging my experience and relationships to further enhance the profiles of Actinium s drug candidates to the hematology and bone marrow transplant community while positioning them for future success. (salesandmarketingnetwork.com)
  • We are currently conducting clinical trials for our three product candidates, Iomab-B, Actimab-A and Actimab-M, as well as performing research on other potential drug candidates utilizing our proprietary actinium-225 technology platform. (businessinsider.com)
  • We expect our Actinium-225 Technology Platform will generate additional drug candidates that we will progress in clinical trials ourselves and or out-license. (businessinsider.com)
  • He suggests that hindsight criticism of the early publications should be mitigated by the then nascent state of radiochemistry: highlighting the prudence of Debierne's claims in the original papers, he notes that nobody can contend that Debierne's substance did not contain actinium. (wikipedia.org)
  • Debierne's name was adopted, however, because he discovered actinium first. (encyclopedia.com)
  • SAB is comprised of independent physicians considered to be key opinion leaders in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B, the Company's lead asset. (medindia.net)
  • The Department of Energy's Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer. (news-medical.net)
  • Or, contact the owner Actinium Pharmaceuticals, Inc. of the FIGHTING CANCER, CELL BY CELL trademark by filing a request to communicate with the Legal Correspondent for licensing, use, and/or questions related to the FIGHTING CANCER, CELL BY CELL trademark. (trademarkia.com)
  • Naturally occurring actinium is very rare in the Earth 's crust. (encyclopedia.com)